Education
About Us
Working with TipRanks
Follow Us
Nurix Therapeutics, Inc. (NRIX)
:NRIX
NRIX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.18 - $29.56
Previous CloseN/A
Volume302.00K
Average Volume (3M)1.11M
Market Cap
$696.79M
Enterprise Value$767.96M
Total Cash (Recent Filing)-$39.04M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.40
Next Earnings
Jul 10, 2025EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.81
Shares Outstanding76,235,596
10 Day Avg. Volume1,486,027
30 Day Avg. Volume1,110,442
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)18.07
Price to Cash Flow (P/CF)-5.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit14.08
Enterprise Value/Ebitda-3.91
Forecast
1Y Price Target
$30.19Price Target Upside230.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
---
Bulls Say, Bears Say
Bulls Say
Cash PositionThe company maintains a strong cash position (~$550M) with runway into 1H:27.
Financial PerformanceNurix received $18.5M in collaboration revenue in 1Q:25 and an additional $15M license extension fee from Sanofi after the quarter ended.
Regulatory ApprovalNX-5948 received FDA orphan drug designation for Waldensrom macroglobulinemia.
Bears Say
Clinical RisksRisks include, but are not limited to: negative clinical proof-of-concept for either NX-2127, NX-5948, NX-1607.
CompetitionThere is notable competition in the space with ONC's BTK degrader BGB-16673 already advancing in a pivotal Ph 2.
Competitive LandscapeValue creation with bexobrutideg is complicated by the robust competitive landscape and tough development path.
---
Ownership Overview
4.87% Insiders
27.21% Mutual Funds
6.13% Other Institutional Investors
45.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NRIX FAQ
What was Nurix Therapeutics, Inc.’s price range in the past 12 months?
Nurix Therapeutics, Inc. lowest stock price was $8.18 and its highest was $29.56 in the past 12 months.
What is Nurix Therapeutics, Inc.’s market cap?
Nurix Therapeutics, Inc.’s market cap is $696.79M.
When is Nurix Therapeutics, Inc.’s upcoming earnings report date?
Nurix Therapeutics, Inc.’s upcoming earnings report date is Jul 10, 2025 which is in 87 days.
How were Nurix Therapeutics, Inc.’s earnings last quarter?
Nurix Therapeutics, Inc. released its earnings results on Apr 08, 2025. The company reported -$0.67 earnings per share for the quarter, beating the consensus estimate of -$0.762 by $0.092.
Is Nurix Therapeutics, Inc. overvalued?
According to Wall Street analysts Nurix Therapeutics, Inc.’s price is currently Undervalued.
Does Nurix Therapeutics, Inc. pay dividends?
Nurix Therapeutics, Inc. does not currently pay dividends.
What is Nurix Therapeutics, Inc.’s EPS estimate?
Nurix Therapeutics, Inc.’s EPS estimate is -0.73.
How many shares outstanding does Nurix Therapeutics, Inc. have?
Nurix Therapeutics, Inc. has 76,235,596 shares outstanding.
What happened to Nurix Therapeutics, Inc.’s price movement after its last earnings report?
Nurix Therapeutics, Inc. reported an EPS of -$0.67 in its last earnings report, beating expectations of -$0.762. Following the earnings report the stock price went up 3.672%.
Which hedge fund is a major shareholder of Nurix Therapeutics, Inc.?
Currently, no hedge funds are holding shares in NRIX
---
Nurix Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.19 (230.31% Upside)
$30.19 (230.31% Upside)
Blogger Sentiment
Bullish
NRIX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 885.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.6%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.89%
12-Months-Change
Fundamentals
Return on Equity
-64.16%
Trailing 12-Months
Asset Growth
96.70%
Trailing 12-Months
Company Description
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. (NRIX) is a biopharmaceutical company focused on the discovery, development, and commercialization of therapies that modulate protein levels as a means of treating a broad range of diseases. The company leverages its proprietary drug discovery platform, DELigase, to develop small molecule inhibitors of E3 ligases, enzymes that play a critical role in the ubiquitin-proteasome system, which regulates protein degradation in cells. Nurix's therapeutic programs primarily target oncology and immune disorders, aiming to address unmet medical needs in these areas.
---
NRIX Stock 12 Month Forecast
Average Price Target
$30.19
▲(230.31% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Intellia Therapeutics
―
Arcus Biosciences
―
Arvinas Holding Company
―
Mineralys Therapeutics, Inc.
―
Best Analysts Covering NRIX
1 Year
1 Year Success Rate
9/19 ratings generated profit
1 Year Average Return
+54.13%
reiterated a buy rating 6 days ago
Copying Christopher Liu's trades and holding each position for 1 Year would result in 47.37% of your transactions generating a profit, with an average return of +54.13% per trade.
---